NEWS
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia –
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announces new vocal biomarker data from Phase 3 RECOVER trial of brilaroxazine in schizophrenia was presented during a virtual key opinion leader event hosted by the Company on September 4, 2024 featuring Brian Kirkpatrick, MD, MSPH (Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Arkansas) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). A replay of the event can be found at https://revivapharma.com/events/.
"Brilaroxazine has demonstrated a safety profile comparable to placebo, with broad spectrum efficacy across the major symptom domains of schizophrenia, including negative symptoms," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "These new vocal biomarker data provide an objective tool that further supports the primary and secondary endpoints evaluated in the RECOVER trial. We look forward to further evaluating vocal biomarker data from patients in our ongoing open label extension study with topline data expected in the fourth quarter of the year."
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announces new vocal biomarker data from Phase 3 RECOVER trial of brilaroxazine in schizophrenia was presented during a virtual key opinion leader event hosted by the Company on September 4, 2024 featuring Brian Kirkpatrick, MD, MSPH (Professor, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Arkansas) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute, New York). A replay of the event can be found at https://revivapharma.com/events/.
"Brilaroxazine has demonstrated a safety profile comparable to placebo, with broad spectrum efficacy across the major symptom domains of schizophrenia, including negative symptoms," said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. "These new vocal biomarker data provide an objective tool that further supports the primary and secondary endpoints evaluated in the RECOVER trial. We look forward to further evaluating vocal biomarker data from patients in our ongoing open label extension study with topline data expected in the fourth quarter of the year."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2329Followers
106Following
24KVisitors
Follow